• 1
    Nordin AJ. Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynecol Surv 1994; 49: 34961.
  • 2
    Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. Cancer 2000; 89: 207684.
  • 3
    Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953–97. Int J Cancer 2003; 104: 6435.
  • 4
    Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989; 35: 2369.
  • 5
    Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish cancer registry in a five-year period. Acta Oncol 1989; 28: 711.
  • 6
    Rosen AC, Ausch C, Hafner E, Klein M, Lahousen M, Graf AH, Reiner A and the Austrian Cooperative Study Group for Fallopian Tube Carcinoma. A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Eur J Cancer 1998; 34: 17259
  • 7
    Rosen AC, Klein M, Hafner E, Lahousen M, Graf AH, Reiner A and the Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Management and prognosis of primary fallopian tube carcinoma. Gynecol Obstet Invest 1999; 47: 4551
  • 8
    Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 2001; 81: 1509.
  • 9
    Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary fallopian tube carcinoma. Obstet Gynecol Surv 2005; 60: 24752.
  • 10
    Jacobs AJ, McMurray EH, Parham J, Kao MS, Galakatos AE, Perez CA, Camel HM. Treatment of carcinoma of the fallopian tube using cisplatin, doxorubicin, and cyclophosphamide. Am J Clin Oncol 1986; 9: 4369.
  • 11
    Hellstrom AC, Silfversward C, Nilsson B, Pettersson F. Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer 1994; 4: 395400.
  • 12
    Riska A, Alfthan H, Finne P, Jalkanen J, Sorvari T, Stenman UH, Leminen A. Preoperative serum hCGβ as a prognostic marker in primary fallopian tube carcinoma. Tumour Biol 2006; 27: 439.
  • 13
    Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336: 112530.
  • 14
    Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001; 80: 3415.
  • 15
    Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002; 346: 16602.
  • 16
    Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 136572.
  • 17
    Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Seow A, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 15966.
  • 18
    Scelo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Andersen A, Tracey E, Brewster DH, McBride ML, Kliewer EV, Tonita JM, Pompe-Kirn V, et al. Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 2006; 118: 18996.
  • 19
    Muir CS, Percy C. Classification and coding for neoplasms. In: JensenOM, ParkinDM, MacLennanR, MuirCS, SkeetRG, eds. Cancer registration: principles and methods. Lyon: IARC Scientific Publication, 1991. 6481. IARC scientific publication no. 95.
  • 20
    Whelan SL. Classification and coding. In: ParkinDM, WhelanSL, FerlayJ, TeppoL, ThomasDL, eds. Cancer incidence in five continents. Lyon: IARC, 2003. 3541.
  • 21
    Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 12504.
  • 22
    McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321: 6248.
  • 23
    Yoonessi M. Carcinoma of the fallopian tube. Obstet Gynecol Surv 1979; 34: 25770.
  • 24
    Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999; 72: 36779.
  • 25
    Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995; 57: 128497.
  • 26
    Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C, Margolese R, Carter R, McGillivray B. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet 1995; 95: 54550.
  • 27
    Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76: 4550.
  • 28
    Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 132734.
  • 29
    Bermejo JL, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 and BRCA2 mutation testing. Ann Oncol 2004; 15: 183441.
  • 30
    Pukkala E, Kesminiene A, Poliakov S, Ryzhov A, Drozdovitch V, Kovgan L, Kyyrönen P, Malakhova I, Gulak L, Cardis E. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer 2006; 119: 6518.
  • 31
    Eddy GL, Copeland LJ, Gershenson DM, Atkinson EN, Wharton JT, Rutledge FN. Fallopian tube carcinoma. Obstet Gynecol 1984; 64: 54652.
  • 32
    Schray MF, Podratz KC, Malkasian GD. Fallopian tube cancer: the role of radiation therapy. Radiother Oncol 1987; 10: 26775.
  • 33
    Kojs Z, Urbanski K, Reinfuss M, Karolewski K, Klimek M, Pudelerk J, Mitus J. Whole abdominal external beam radiation in the treatment of primary carcinoma of the fallopian tube. Gynecol Oncol 1997; 65: 4737.
  • 34
    Wolfson AH, Tralins KS, Greven KM, Kim RY, Corn BW, Kuettel MR, Philippart C, Raub WA,Jr, Randall ME. Adenocarcinoma of the fallopian tube: results of a multi-institutional retrospective analysis of 72 patients. Int J Radiat Oncol Biol Phys 1998; 40: 716.
  • 35
    Travis LB, Curtis RE, Boice JD,Jr, Platz CE, Hankey BF, Fraumeni JF,Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996; 56: 156470
  • 36
    Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst 1992; 84: 30612.
  • 37
    Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340: 3517.
  • 38
    Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 1999; 13: 173540.
  • 39
    See HT, Thomas DA, Bueso-Ramos C, Kavanagh J. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer 2006; 16: 23640.
  • 40
    Dreyer L, Winther JF, Pukkala E, Andersen A. Avoidable cancers in the Nordic countries. Tobacco smoking. APMIS 1997; 76: 947.